ReviewNature protocols2026
Preparation of polycaprolactone-based 2D platelets via living crystallization-driven self-assembly.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we describe the preparation of two-dimensional (2D) polymer platelets based on poly(ε-caprolactone) (PCL) using living crystallization-driven self-assembly (CDSA), a seeded growth strategy that uses crystallization as a directional driving force to achieve epitaxial growth with controlled size and shape. The method integrates ring-opening polymerization for preparation of PCL segments, reversible addition-fragmentation chain-transfer polymerization for corona-forming blocks, sonication fragmentation or the flash-freezing method to generate seed particles and living CDSA to produce uniform and monodisperse 2D nanostructures. These 2D platelets are prepared from mixtures of PCL-based homopolymers and PCL-b-PDMA block copolymers, where PDMA refers to poly(N,N-dimethylacrylamide); similar solvophilic blocks with comparable properties could also be employed in place of PDMA. In this system, the semicrystalline PCL block provides the driving force for self-assembly, while the amorphous solvophilic corona block imparts colloidal stability and tunes interfacial properties. Owing to the living nature of CDSA, the platelet dimensions scale linearly with the unimer-to-seed ratio, enabling reproducible control over platelet area, layered structures and overall morphology. The Protocol is compatible with a broad range of PCL-based polymers bearing diverse functional groups and corona chemistries, and it can be readily adapted to incorporate responsive, supramolecular or fluorescent components. The resulting 2D platelets serve as versatile model systems for probing CDSA mechanisms and as platforms for optical and stimuli-responsive materials. The complete workflow-from polymer synthesis to structural characterization-can be completed within ~2 weeks and can be performed by researchers with basic experience in polymer synthesis and self-assembly.
Identifiers
42642617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.